BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD

Commercial success of VINIA validates the power of BioHarvest's patented Botanical Synthesis technology to produce valuable plant-based Compounds at industrial scale

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 18, 2025) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that its Red Grape Cell composition - known commercially as VINIA® - has now exceeded $50 Million USD in cumulative sales with the vast majority of sales occurring since launching in the US less than 4 years ago.

VINIA®, a red grape cell-based supplement, is produced by BioHarvest's proprietary Botanical Synthesis platform technology. VINIA® was launched in the United States as a direct-to-consumer product in May 2021, and as of February 16^th 2025, has also achieved a major milestone of over 50,000 active U.S. users on recurring subscription packages.

BioHarvest has conducted a number of clinical trials on VINIA® to support its heart-health claims, which includes a clinical trial that demonstrated VINIA's ability to significantly increase dilation of arteries and improve overall blood flow. In the USA, VINIA® has received approximately 8,000 customer reviews with a verified rating of 4.8/5*. The growing active subscription base and positive customer reviews are a testimonial of the efficacy of the product and its growth potential both in the U.S. and globally.

As a reflection of the Company's confidence in the trajectory of the business, BioHarvest plans to support future growth by expanding its production capacity by 4x with the building of a new 100 ton per year production facility, expected to be operational in late 2026.

"We spent 15 years and over $100M to develop the Botanical Synthesis Process Technology," said BioHarvest CEO Ilan Sobel. "The VINIA red grape cell molecule was the first composition developed on our platform and is now a powerful validation that our Botanical Synthesis technology can create highly efficacious, patentable, plant-based molecules at scale."

"In addition to the compounds within our Products division pipeline, our growing CDMO Services division now has multiple compounds being developed under contract with Pharmaceutical and Nutrition industry partners. I am confident that we have the plan and the team in place to achieve our vision of developing life-changing compounds from plants that improve the health and wellness of millions of people, whilst preserving the planet for generations to come," concluded Sobel.